Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	47.89	45.79	35.44	11.36	55.74	32.59
Short-Term Investments	0.02	2.02	0.05	46.52	2.62	8.98
Cash & Short-Term Investments	47.91	47.81	35.49	57.88	58.36	41.56
Cash Growth	9.82%	34.69%	-38.67%	-0.83%	40.41%	35.31%
Accounts Receivable	0.21	0.64	0.75	0.3	50.84	0
Receivables	0.21	0.64	0.75	0.3	50.84	0
Prepaid Expenses	1.87	2.55	2.2	1.83	2.35	2.36
Restricted Cash	-	-	-	-	-	0.08
Total Current Assets	49.98	51	38.44	60	111.55	44
Property, Plant & Equipment	4.05	4.4	4.77	5.67	4.87	5.63
Goodwill	10.67	10.67	10.67	10.67	10.67	10.67
Other Intangible Assets	46.54	46.54	46.56	46.69	46.82	47.03
Other Long-Term Assets	0.5	0.61	0.58	0.63	0.63	0.62
Total Assets	111.75	113.22	101.02	123.66	174.55	107.95
Accounts Payable	4.98	1.17	2.05	2.39	3.54	2.61
Accrued Expenses	-	4.26	4.22	6.22	24.25	3.67
Short-Term Debt	-	-	-	-	-	0.52
Current Portion of Leases	1.18	1.15	0.88	0.95	0.83	0.76
Current Unearned Revenue	6.93	7.39	10.81	9.42	18.12	0.19
Other Current Liabilities	-	-	-	-	0.38	0.01
Total Current Liabilities	13.09	13.98	17.96	18.98	47.12	7.77
Long-Term Leases	1.06	1.36	2.07	2.94	1.97	2.54
Long-Term Unearned Revenue	13.61	14.43	18.69	27.73	32.45	-
Long-Term Deferred Tax Liabilities	0.27	0.27	0.27	2.08	2.08	2.08
Other Long-Term Liabilities	6.06	6.16	-	0	0.03	0.44
Total Liabilities	34.1	36.21	39	51.73	83.65	12.82
Common Stock	489.31	484.72	451.34	440.28	434.53	393.94
Retained Earnings	-407.6	-403.47	-384.86	-363.37	-337.1	-294.08
Comprehensive Income & Other	-2.68	-2.88	-3.07	-3.57	-5.21	-3.67
Total Common Equity	79.03	78.38	63.42	73.34	92.22	96.2
Minority Interest	-1.37	-1.37	-1.4	-1.4	-1.32	-1.07
Shareholders' Equity	77.66	77.01	62.02	71.94	90.9	95.13
Total Liabilities & Equity	111.75	113.22	101.02	123.66	174.55	107.95
Total Debt	2.24	2.51	2.95	3.9	2.8	3.83
Net Cash (Debt)	45.66	45.29	32.54	53.98	55.56	37.74
Net Cash Growth	13.11%	39.19%	-39.72%	-2.84%	47.22%	47.71%
Net Cash Per Share	0.22	0.23	0.19	0.32	0.34	0.25
Filing Date Shares Outstanding	228.36	228.36	188.53	170.15	169.71	161.64
Total Common Shares Outstanding	228.36	220.42	174.99	170.09	169.48	153.1
Working Capital	36.9	37.02	20.48	41.02	64.43	36.23
Book Value Per Share	0.35	0.36	0.36	0.43	0.54	0.63
Tangible Book Value	21.82	21.17	6.19	15.98	34.73	38.5
Tangible Book Value Per Share	0.10	0.10	0.04	0.09	0.20	0.25
Machinery	-	4.13	3.61	3.26	3.47	3.63
Leasehold Improvements	-	2.3	2.31	2.15	2.54	2.47

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q